Orexigen Therapeutics (OREX) Posts Q1 GAAP EPS of $1.12

Orexigen Therapeutics (NASDAQ: OREX) reported Q3 EPS of $1.12, which might not compare with the analyst estimate of ($2.24). Revenue for the quarter came in at $7 million versus the consensus estimate of $8.17 million.

For the three months ended September 30, 2016, Orexigen reported net income of $47.7 million, or $3.27 per basic share, as compared to a net loss of $11.1 million, or $0.86 per basic share, for the third quarter of 2015. Excluding the elimination of deferred revenue and other business combination accounting adjustments associated with the completed acquisition of U.S. rights to Contrave, Orexigen would have incurred a net loss of $30.2 million for the three months ended September 30, 2016. A reconciliation from reported GAAP net income to non-GAAP net loss is provided at the end of this press release.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• ATN International (ATNI) Misses Q1 EPS by 46c ; Offers Guidance
• ESSA Bancorp (ESSA) Tops Q2 EPS by 13c
• First Bancorp. (FBNC) Misses Q1 EPS by 2c